1.    What Should Heather Bresch do? Why? What Risks do you see with this plan of action?

2.    Does the variation in prices across countries seem reasonable? What would happen if Mylan were forced to make its prices more consistent?

3.    What changes, if any, would you make to Mylans pricing policy? Is there a better way to structure the discounts?

4.    What is the biggest risk that Bresch faces?

5.    What can leaders learn from the EpiPen case?